Programs & Partners
It is our ambition that our technology will underpin the development and commercialisation of the next generation of DNA products.
We are therefore working in collaboration with big pharma, leading biotechs and esteemed academics and research institutes, to leverage our dbDNA™ platform in areas of high unmet need where dbDNA™ may offer unique or improved therapies or devices.
We are working in partnership with the University of Southampton and the University of Liverpool to develop a therapeutic DNA vaccine, TGL-100, for head and neck squamous cell carcinoma (HNSCC).
Cancer vaccines present antigens that prime the immune system, driving it to attack cancer. These therapies have shown significant promise in clinical studies, but use has been limited by slow and expensive manufacturing. Touchlight’s technology will allow for larger scale production, enabling improved availability.
The clinical trial to test TGL-100 in HNSCC patients with recurrent metastatic disease is anticipated to start towards the end of 2023.
Our dbDNA™ technology is uniquely suited to enabling rapid, global-scale production of vaccines as a pandemic countermeasure for emerging infectious diseases.
As well as supplying material for other COVID-19 vaccine programs, we are working with a team of vaccine development and infectious and respiratory disease experts to develop a DNA SARS-CoV-2 vaccine.
We aim to develop a vaccine that can be delivered via minimally invasive routes that induce strong mucosal and systemic immunity, and will eliminate the necessity for cold chain in distribution.
We are seeking strategic collaborations
If you’re interested in collaborating or partnering with Touchlight to use our dbDNA™ platform to advance the next generation of DNA products, we’d like to hear from you.Get in touch